Pfizer Warns Against Applying Generic Policies To Biosimilars
Global Biosimilars Commercial Lead Roman Irsiegler Talks Market Sustainability
Pfizer’s biosimilars commercial lead, Roman Irsiegler, has set out his views on policy obstacles for biosimilars that need to be addressed if the market is to sustainably deliver on its potential.
You may also be interested in...
The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.
Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”
Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.